Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5111-5115

  Fukushima, Toshihiro ^a   Takemura, Haruyuki ^a   Yamashita, Taro ^a   Ishisaka, Taizo ^a   Inai, Kunihiro ^a   Imamura, Shin ^a   Urasaki, Yoshimasa ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Acute leukemia; Atypical multidrug resistance; DNA cleavage; Multidrug resistance; Topoisomerase II; VP 16

Indexed keywords

ACLARUBICIN; CAMPTOTHECIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; IDARUBICINOL; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DNA CLEAVAGE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATALYSIS; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; K562 CELLS; LEUKEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033399645     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
2. Tsuruo T: Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 79: 285-296, 1988.
3. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
4. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT: Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869, 1988.
5. Deffie AM, Batra JK, Goldenberg GJ: Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
6. Mirski SEL, Evans CD, Almquist KC, Slovak ML, Cole SPC: Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53: 4866-4873, 1993.
7. Vassetzky YS, Alghisi G-C, Gasser SM: DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays 17: 767-774, 1995.
8. Campling BG, Baer KA, Gerlach JH, Lam Y-M, Cole SPC, Mirski SEL: Topoisomerase II levels and drug response in small cell lung cancer. Int J Oncol 10: 885-893, 1997.
9. Harker WG, Slade DL, Drake FH, Parr RL: Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug- induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 30: 9953-9961, 1991.
10. Simon SM, Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504, 1994.
11. Lai G-M, Moscow JA, Alvarez MG, Fojo AT, Bates SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688-695, 1991.
12. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
13. Posada J, Vichi P, Tritton TR: Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 49: 6634-6639, 1989.
14. Urasaki Y, Ueda T, Yoshida A, Fukushima T, Takeuchi N, Tsuruo T, Nakamura T: Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res 16: 709-714, 1996.
15. Hamada H, Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
16. Fukushima T, Ueda T, Uchida M, Nakamura T: Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol 57: 121-130, 1993.
17. Chu G, Vollrath D, Davis RW: Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science 234: 1582-1585, 1986.
18. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301, 1987.
19. Paoletti C: The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs. Pharmacol Ther 60: 381-387, 1993.
20. Glisson B, Gupta R, Smallwood-Kentro S, Ross W: Characterization of aquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934-1938, 1986.
21. Lee MS, Wang JC, Beran M: Two independent amsacrin-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223: 837-843, 1992.
22. Malonne H, Atassi G: DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anti-cancer Drugs 8: 811-822, 1997.
23. Jensen PB, Sørensen BS, Demant EJF, Sehested M, Jensen PS, Vindeløv L, Hansen HH: Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase Ii-mediated DNA cleavage. Cancer Res 50: 3311-3316, 1990.
24. Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O, Hansen HH: Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 52: 5093-5099, 1991.
25. Nitiss JL, Pourquier P, Pommier Y: Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 57: 4564-4569, 1997.
26. Bridewell DJA, Finlay GJ, Baguley BC: Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol Res 9: 535-542, 1997.
27. Chen M, Beck WT: Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53: 5946-5953, 1993.
28. Jensen PB, Sørensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E, Hansen HH: Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035, 1993.
29. Fukushima T, Kawai Y, Urasaki Y, Yoshida A, Ueda T, Nakamura T: Influence of idarubicinol on the antileukemic effect of idarubicin. Leukemia Res 18: 943-947, 1994.
30. Fukushima T, Inoue H, Takemura H, Kishi S, Yamauchi T, Inai K, Nakayama T, Imamura S, Urasaki Y, Nakamura T, Ueda T: Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin. Leukemia Res 22: 625-629, 1998.
31. Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI: Aclarubicin in the treatment of acute nonlymphocytic leumemia refractory to treatment with daunorubicin and cytarabine: a Phase II trial. Cancer Treat Rep 68: 1233-1238, 1984.
32. Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, Hancock C, Williams L, Stevens Y-W, Clarkson BD, Young C: 4- demethoxydaunorubicin (idarubicin) in combination with 1-β-D- arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Res 49: 477-481, 1989.
33. Twentyman PR: Transport proteins in drug resistance: biology and approaches to circumvention. J Int Med 242 (Suppl 740): 133-137, 1997.
34. Fukushima T, Yamashita T, Yoshio N, Misaki H, Yamauchi T, Imamura S, Urasaki Y, Ueda T: Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells. Leukemia Res 23: 37-42, 1999.